<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE296nnn/GSE296649/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296649</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Clonal evolution permits outgrowth of chemoresistant LMPP-like early progenitors in relapsed NPM1c AML [scRNA-Seq]</name><description>The most recurrent acute myeloid leukemia (AML) driver in adult patients is a DNA frameshift insertion in the Nucleophosmin 1 (NPM1) gene. This mutation causes a translocation of the coding protein from the nucleus to the cytoplasm (NPM1c). We have generated paired single-cell multi-omics profiles for ~205,000 bone marrow cells collected from NPM1c AML patients at diagnosis and relapse. Detailed single-cell clonal analysis unveiled the evolution, expansion, and concomitant phenotypic changes of pathogenic AML (sub)clones. Blasts with an internal tandem duplication in the FLT3 gene (FLT3-ITD+ blasts) were often lowly abundant at diagnosis but expanded drastically at relapse at the expense of other blasts. Intriguingly, genetically identical FLT3-ITD+ blasts switched from granulocyte-monocyte progenitor-like at diagnosis toward more immature lympho-myeloid primed progenitor (LMPP)-like blasts at relapse. Our data shows that clonal evolution and the accumulation of a FLT3-ITD, is a key evolutionary event that alters AML blast plasticity with minimal changes in the blast phenotype. Increased plasticity favors the specific selection and expansion of FLT3-ITD+ blasts, which adopt a unique LMPP-like phenotype. The overriding transition between diagnosis and relapse suggests that therapeutic interventions (against proliferating cells) could license or accelerate this shift, highlighting the need for a tailored drug composition to target relapsed NPM1c AML.</description><dates><publication>2026/05/01</publication></dates><accession>GSE296649</accession><cross_references><GSM>GSM8974228</GSM><GSM>GSM8974227</GSM><GSM>GSM8974229</GSM><GSM>GSM8974220</GSM><GSM>GSM8974222</GSM><GSM>GSM8974221</GSM><GSM>GSM8974224</GSM><GSM>GSM8974223</GSM><GSM>GSM8974226</GSM><GSM>GSM8974225</GSM><GSM>GSM8974196</GSM><GSM>GSM8974195</GSM><GSM>GSM8974239</GSM><GSM>GSM8974238</GSM><GSM>GSM8974198</GSM><GSM>GSM8974231</GSM><GSM>GSM8974230</GSM><GSM>GSM8974197</GSM><GSM>GSM8974233</GSM><GSM>GSM8974232</GSM><GSM>GSM8974199</GSM><GSM>GSM8974235</GSM><GSM>GSM8974234</GSM><GSM>GSM8974237</GSM><GSM>GSM8974236</GSM><GSM>GSM8974240</GSM><GSM>GSM8974206</GSM><GSM>GSM8974205</GSM><GSM>GSM8974249</GSM><GSM>GSM8974208</GSM><GSM>GSM8974207</GSM><GSM>GSM8974209</GSM><GSM>GSM8974242</GSM><GSM>GSM8974241</GSM><GSM>GSM8974244</GSM><GSM>GSM8974200</GSM><GSM>GSM8974243</GSM><GSM>GSM8974202</GSM><GSM>GSM8974246</GSM><GSM>GSM8974201</GSM><GSM>GSM8974245</GSM><GSM>GSM8974204</GSM><GSM>GSM8974248</GSM><GSM>GSM8974247</GSM><GSM>GSM8974203</GSM><GSM>GSM8974251</GSM><GSM>GSM8974250</GSM><GSM>GSM8974217</GSM><GSM>GSM8974216</GSM><GSM>GSM8974219</GSM><GSM>GSM8974218</GSM><GSM>GSM8974252</GSM><GSM>GSM8974211</GSM><GSM>GSM8974210</GSM><GSM>GSM8974213</GSM><GSM>GSM8974212</GSM><GSM>GSM8974215</GSM><GSM>GSM8974214</GSM><GPL>18573</GPL><GPL>24676</GPL><GSE>296649</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>